CompletedPhase 3NCT00404612
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
Studying Anterior uveitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lux Biosciences, Inc.
- Principal Investigator
- Eddy Anglade, M.D., MDChief Medical Officer
- Intervention
- Placebo(drug)
- Enrollment
- 218 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 2007 – 2009
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Retinal Consultants of Arizona, Phoenix, Arizona, United States
- University of Illinois - Chicago, Chicago, Illinois, United States
- Midwest Eye Institute, Indianapolis, Indiana, United States
- Wilmer Eye Institute, Baltimore, Maryland, United States
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
- Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts, United States
- Associated Retinal Consultants, PC, Grand Rapids, Michigan, United States
- Tauber Eye Center, Kansas City, Missouri, United States
- UMDNJ-New Jersey Medical School, Ophthalmology Dept., Newark, New Jersey, United States
- New York Eye & Ear Hospital, New York, New York, United States
- Duke University Eye Center, Erwin Road, Durham, North Carolina, United States
- Oregon Health Sciences University, Portland, Oregon, United States
- Texas Retina Associates, Arlington, Texas, United States
- Retina Research Center, Austin, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00404612 on ClinicalTrials.govOther trials for Anterior uveitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07285070Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior UveitisNovaliq GmbH
- RECRUITINGPHASE2NCT07552012A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIUShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07218770A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT07262437Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine ProfilesUniversity of Milan
- ACTIVE NOT RECRUITINGPHASE3NCT06431373A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisPriovant Therapeutics, Inc.
- RECRUITINGNCT07065747Quantification & Classification of Inflammatory Cells in Uveitis Using OCTOregon Health and Science University
- RECRUITINGNCT06720376Observational Prospective Turkish Inception Cohort of Uveitis and SpondyloarthritisMarmara University
- RECRUITINGPHASE3NCT05486468The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior SegmentTexas Retina Associates